Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).
Neeraj Agarwal
No relevant relationships to disclose
Kinjal Parikh
No relevant relationships to disclose
Srinivas Kiran Tantravahi
No relevant relationships to disclose
Hilda Crispin
No relevant relationships to disclose
Joan Van Atta
No relevant relationships to disclose
Julia Anne Batten
No relevant relationships to disclose
Daniel Sageser
No relevant relationships to disclose
Wolfram E. Samlowski
No relevant relationships to disclose
Kenneth F. Grossmann
No relevant relationships to disclose
Junfeng Wang
No relevant relationships to disclose
David D. Stenehjem
No relevant relationships to disclose